Drug Database
RA

rabies vaccine

✓ Approved

China National Biotec Group · Vaccine · Vaccine

What is rabies vaccine?

rabies vaccine is a vaccine developed by China National Biotec Group. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

CompanyChina National Biotec Group
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, China National Biotec Group

Therapeutic Indications

rabies vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsRabies✓ Approved

Related Research Articles

PubMedVeterinary medicine international2026-09-20

Pattern of Cytopathic Effects Produced by Recent Bangladeshi Field Isolates of PPR Virus in Vero Cells and Preparation of Purified Viral Antigen.

Siddiqui M S I MSI, Begum Jahan Ara JA, Islam M R MR, Chowdhury E H EH

This study was conducted to explore the pattern of appearance of cytopathic effect (CPE) produced by a Bangladeshi strain of Peste des petits ruminant's virus (PPRV) in Vero cells during serial passaging, to estimate the virus titer and concentration of PPR viral RNA at different passage levels, and to find out a suitable passage level for viral antigen purification. Five isolates of PPR virus from local outbreaks were isolated, confirmed with conventional RT-PCR, and then used as viral inoculant in Vero cells and lamb kidney cell culture (LKC). Morphology of CPE's and pattern of development of CPE were studied and recorded at different passage levels and days postinfection (dpi). Tissue culture fluid (TCF) was used to prepare purified viral antigen by ultracentrifugation and for quantitation by spectrophotometry. Viral titers were determined following an endpoint dilution assay. The study revealed that the CPE was not perceptible in all isolates until 11 dpi for the first six passages. The virus was not detected in TCF of both infected and control flasks by RT-PCR up to the 6th passage. The first CPE appeared on 5 dpi at the 7th passage level for all isolates. The CPE was characterized by initial cell rounding, followed by the formation of small syncytia, progression to total cell infection, and eventual complete detachment of the cell monolayer. Maximum titer (3.5 Log10TCID50) and RNA concentration (260 ng/µL) were found at the 30th passage level by one isolate (Isolate-F). It is concluded that initiation of CPE production in Vero cells by the Bangladeshi field strain of PPR virus occurs at the 7th passage level. Virus titer and concentration of PPR viral RNA increased with the advancement of passaging, and these are highly related to each other. TCF at higher passage levels, such as the 60th passage, is most suitable for purification of PPR viral antigen.

PMID 42763559
Read full article →
PubMedAdvances in virology2026-09-20

Comparative Sequence Analysis of the Envelope Gene of Kyasanur Forest Disease Virus Vaccine Strain With Currently Circulating Field Strains.

Kaje Keerthi K, Marinaik Chandranaik B CB, Gomes Amitha Reena AR, Rizwan Apsana A et al.

The present study was undertaken with the objective of performing comparative sequence analysis of the envelope (E) gene of Kyasanur forest disease virus (KFDV) vaccine strain P9605 with the circulating field strains. The study was taken up as the currently used KFDV vaccine strain, KFDV P9605, was isolated in the 1960s. For this study, we designed two sets of primers targeting the complete amplification of the E gene of KFDV. The sequencing was performed by the Sanger method, and the deduced sequence of the vaccine virus was deposited in GenBank with accession number PX067005. This sequence obtained for the vaccine virus was aligned and compared with sequences of GenBank-deposited circulating field strains. We also performed comparative sequence analysis of the Kyasanur forest disease (KFD) vaccine seed virus having passaged twice in mouse brain with the vaccine seed virus passaged six times in mouse brain to investigate whether multiple passages in mouse brain will lead to genetic mutation in the immunologically important E gene. The phylogenetic analysis revealed seven amino acid mutations in the field strains at positions A123T, S158N, D178E, D239N, A313S, M429I, and G479A when compared with the vaccine strain. We did not find any mutations at the critical fusogenic segment (residues 98-113) in the E gene of currently circulating field strains compared to the vaccine seed virus. The study found no genetic variations in the E gene of the KFD virus passed two times and passed six times in mouse brain. We performed SWISS-MODEL homology modeling, AlphaFold protein analysis, and Ramachandran plot analysis to study the E protein structures and stability. The observations made in this study suggest slow evolutionary drift and conserved structural stability of the envelope gene of KFDV ever since its emergence 7 decades ago; however, the functional implications of these amino acid substitutions need further studies on their roles in viral infectivity, transmission, and impact on immunity.

PMID 42763584
Read full article →
PubMedClinical ophthalmology (Auckland, N.Z.)2026-09-20

Optimizing Cataract Surgery Workflows Across a Multi-Satellite Tertiary Care Center.

El Ashry Ahmed A, El Ashry Mahmoud M, Kang Sujin S, Palioura Sotiria S et al.

Cataract surgery requires precise coordination of multimodal processes delivered across decentralized multi-site tertiary healthcare systems. Investigating the logistical orchestration required for geographically distributed healthcare networks, this review describes an operational framework from a multi-satellite tertiary academic referral center operating a hub-and-spoke model across South Florida handling approximately 21,000 annual surgeries. To address multi-site care fragmentation, the institute introduced the "digital spine" framework, which integrates cloud-based diagnostic platforms, coordinated scheduling, and centralized surgical planning. This cloud-integrated system asynchronously bridges diagnostic hubs up to 116 miles apart, sending centralized surgical plans directly to operating room microscopes and feeding post-operative refractive data back into predictive algorithms. Within this network, cataract surgery accounts for approximately 8000 cases annually. Providers, imaging technicians, surgical coordinators, and nurses seamlessly establish collaborative care pathways. This system plays a critical role in maintaining efficiency, while a tiered referral protocol routes high-risk and complex cases to the central hub where multidisciplinary support is available. The present review fills the literature gap by providing a scalable blueprint for multi-site ophthalmic networks seeking to integrate decentralized diagnostics with centralized surgical execution. However, further quantitative studies are needed to evaluate clinical and cost-effectiveness outcomes.

PMID 42763694
Read full article →
PubMedEClinicalMedicine2026-09-20

Artificial intelligence in clinical trials-state of the evidence, gaps, and next steps.

Armoundas Antonis A AA, Tarabanis Constantine C, Loscalzo Joseph J

Artificial intelligence (AI) affects clinical trials in two distinct but overlapping ways: as the intervention under evaluation and as infrastructure supporting trial design, recruitment, monitoring, endpoint assessment, analysis, and reporting. In this manuscript, we define AI-as-intervention as AI whose output is itself part of the assigned clinical intervention being evaluated for its effect on participant care or outcomes, and AI-for-trial-operations as AI used to support trial design, conduct, or analysis without itself constituting the treatment under study. This is an important distinction because AI-as-intervention generally requires prospective clinical evaluation with prespecified estimands, prospectively governed model behaviour, and protocol-level oversight, whereas AI-for-trial-operations is often judged by workflow accuracy, impact of the decision, transportability, and safety under real-world constraints, although some uses, such as endpoint support or inferential modelling, may also require similarly explicit change control and oversight. Using this distinction as an analytical framework rather than as a division into separate parts, we examine how AI can improve each phase of the clinical-trial lifecycle, what evidence currently supports these applications, what limitations constrain their validity and transportability, and what methodological and governance safeguards are required. We synthesise evidence across safety, efficacy, operational risk prediction, network medicine, digital health technologies, retrieval-augmented generation, and agentic workflows, while aligning the discussion to ICH E6(R3), ICH E9(R1), and emerging structured-protocol standards. AAA was partly supported by the Institute of Precision Medicine (17UNPG33840017) from the AHA, the RICBAC Foundation, and NIH grants R01HL173935-01, 1 R01 HL161008-01.

PMID 42763541
Read full article →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-09-20

Financial toxicity among families of children with cancer: a qualitative systematic review and meta-aggregation.

Yang Hui H, Li Chen C, Chen Qian Q, Shu Dan D et al.

To synthesize qualitative evidence on how financial toxicity is experienced, sustained, and managed at the family level in pediatric cancer. A qualitative systematic review using meta-aggregation. PubMed, Web of Science, Embase, PsycINFO, CINAHL, and three major Chinese databases (CNKI, WanFang, VIP) were searched up to May 2025. Two reviewers independently conducted study screening, data extraction, and quality appraisal following Joanna Briggs Institute (JBI) guidelines. Discrepancies were resolved through discussion and team consensus. Meta-aggregation was applied to synthesize findings. Fourteen studies of moderate-to-high methodological quality, involving 524 participants (primarily parents of children with cancer) from seven countries, were included. Thirty-eight initial findings were aggregated into 10 categories and further synthesized into three final findings: (1) Financial toxicity arose from the accumulation of direct medical costs, indirect expenses, income loss due to employment disruption, and inadequate insurance or social support; (2) These financial pressures compromised family economic security and were associated with debt, reduced living standards, long-term financial vulnerability, and psychosocial impacts; (3) Families attempted to manage financial toxicity through external financial assistance and reorganization of life around the child's treatment, although such strategies often provided only partial relief. Financial toxicity in pediatric oncology is a sustained and family-level burden that undermines household stability beyond clinical treatment phases. The limited effectiveness of existing coping strategies highlights structural gaps in supportive care. Early identification of financial risk, family-centered counseling, and coordinated system-level support may mitigate long-term consequences and promote more equitable survivorship outcomes. No patient or public contribution. This review was prospectively registered with PROSPERO, the International Prospective Register of Systematic Reviews (CRD42024519179). Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD42024519179 .

PMID 42763337
Read full article →
PubMedSpinal cord2026-09-20

Blood flow restricted exercise with and without transcutaneous spinal cord stimulation via telehealth in persons with tetraplegia. A protocol for randomized clinical trial.

Gorgey Ashraf S AS, Rehman Muhammad U MU, Wasim Momal M, Khalil Refka E RE et al.

A single site randomized clinical trial; Richmond, VA, USA. To determine the effect of 16 weeks of home-based blood flow restriction-enhanced neuromuscular electrical stimulation (BES) and non-invasive transcutaneous spinal cord stimulation (TSS) with mass practiced (MP) training on cervical neuroplasticity and upper extremity function in individuals with tetraplegia. The program is supported by a telehealth-based approach designed to improve adherence. Forty-four adults (18-70 years) with incomplete cervical SCI (AIS B-D; injury level C8 or above) will be randomized to TSS + BES + MP or sham TSS + BES + MP for 30 weeks. All participants, accompanied by a caregiver, will complete a 4-week education and training phase (2 weeks on-site, 2 weeks via telehealth), followed by 16 weeks of telehealth-supervised home training. Baseline assessments will occur before training (BL1) and after the education phase (Phase 1, BL2). Post-intervention (P1) testing will follow 16 weeks of home-based training (Phase 2), with an additional follow-up (Fw) after an 8-week washout period to evaluate any carry-over effects (Phase 3). The first 15 months will serve as a feasibility phase without randomization; data from these participants will be included within the TSS + BES + MP group. Randomization thereafter will be conducted using a computer-generated sequence. Home-based TSS application for upper extremity function is a feasible and safe strategy in persons with tetraplegia. The proposal is likely to ensure long-term compliance and adherence as well as to reduce the barriers associated with exercise interventions in persons with tetraplegia. National Institute on Disability, Independent Living, and Rehabilitation Research [NIDILRR]. NCT05423600.

PMID 42763327
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rabies vaccine